Superior in Medical Technology

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced positive results from a study comparing subjects randomized to...

Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment

Journal of Vascular & Interventional Radiology Cites Improved Recovery and Quality-of-Life with VNUS Technology SAN JOSE, Calif., June 10 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS ), a worldwide leader in medical devices for the minimally invasive tr...

Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study

SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., March 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ) today announced positive results from DURATION-2, the second in a series of studies designed to...

Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis

Results from the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed Bone Turnover Markers versus Raloxifene in Postmenopausal Women with Osteoporosis ATHENS, Greece, March 23 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) presented new data showing arzoxifene, an inv...

HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients

Landmark trial provides new insight for physicians NATICK, Mass. and WASHINGTON, Oct. 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of the HORIZONS AMI trial. The HORIZONS AMI trial, sponsored by the Cardiovascular ...

Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment

Additional Analysis Shows HUMIRA Effectively Treats Adult Patients with Moderate to Severe Psoriasis Regardless of Age, Duration of Disease, Diagnosis of Psoriatic Arthritis or Recent Systemic Therapy PARIS, Sept. 18 /PRNewswire-FirstCall/ -- More psoriasis patients achieve efficacy when...

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events

New analysis of landmark study showed patients taking prasugrel had lower risk of combined endpoint of recurrent heart attack, stroke or cardiovascular death after first event than those taking clopidogrel TOKYO and INDIANAPOLIS, Aug. 21 /PRNewswire-FirstCall/ -- A new, pre-specified analy...

A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market

Advantages in Efficacy and Delivery Will Make Qnexa the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources WALTHAM, Mass., June 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and ...

Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study

Growing body of evidence shows matrix of polyphenols, as provided in Longevinex(R), exert greater benefit than resveratrol alone. 150-year lifespan not far off? SAN DIMAS, Calif., March 31 /PRNewswire/ -- While molecular biologists and news reporters present jaw-dr...

ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD

WELLESLEY HILLS, Mass., Feb. 19 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced today the design of a clinical trial to investigate whether Chlamydia STD is treated adequately by currently approved antibiotics. Rifalazil, the most ...

Anastrozole Confirmed Superior in Breast Cancer Prevention

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Anastrozole is more effective than tamoxifen at preventing breast cancer recurrence for periods of at least 10 years in women with hormone-responsive cancers. In addition, the increased risk of fractures that has been seen in some patients being treated wit...

IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients

IRVINE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI ) today announced the presentation of updated survival data from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The trial was part of a National Cancer Institute (NCI) funded cooperative group study...

Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg

- Arterial Blockages in the Leg are Estimated to Affect 8 Million Americans - WASHINGTON, Oct. 23 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW ), a world leader in products and technologies to treat advanced cardiovascular disease, today...

Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria

Novel Antibiotic Candidate Rapidly Bactericidal Against Both Cultures and Spores of the Anaerobic Bacterium Using Multiple in Vitro Methods CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released data from two studies comparing the in vitro activity of its lead anti...

Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior

/CAUTION -- ADVANCE FOR RELEASE AT 5 P.M. EST MONDAY, FEB. 4/ /ADVANCE/ ROCKVILLE, Md., Feb. 4 /PRNewswire-USNewswire/ -- Patients who undergo complete prostate removal are less likely to experience urinary incontinence or other complications if the operation is done by an experienced s...

New Phase IV Clinical Study Indicates LidoSite Provides Rheumatology Patients Superior Pain Relief

FAIR LAWN, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), today announced results from a new phase IV "Open Label" clinical study demonstrating that LidoSite, the first FDA approved active patch for dermal analgesia, provided better pain relief to more than 73 ...

Abbott's Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial

- XIENCE V Demonstrates Superiority in Primary Endpoint of In-Segment Late Loss, Non-Inferiority in Major Secondary Endpoint of Target Vessel Failure and Superiority in Major Adverse Cardiac Events (MACE) in the SPIRIT III U.S. Trial - ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Da...

Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data Published in JAMA

Trexima provided superior sustained pain-free results compared to sumatriptan RESEARCH TRIANGLE PARK and CHAPEL HILL, N.C., April 03, 2007 /PRNewswire-FirstCall/ -- -- Findings from two pivotal efficacy studies of more than 2,900 migraine sufferers demonstrated that Trexima(TM) provided superior h...

Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy

VIENNA, Austria, May 23, 2007-The chemotherapy drug docetaxel currently offers the best treatment for androgen-independent prostate cancer. That is the result of a now published clinical trial that compared the efficacy of the two most widely used chemotherapy drugs. When using docetaxel, the risk...

Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) today released top-line findings from its six month study of Proellex in the treatment of endometriosis. This study, conducted in Europe, enrolled 39 premenopausal women and has completed six months of do...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...e competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our pr...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

...xt-generation anabolic treatment for osteoporosis," said C. Richard Lyttle, PhD, President and CEO of Radius. "We are especially encouraged by BA058's superior efficacy in building new bone rapidly, particularly at the femoral neck, since hip fractures are one of the most serious complications of osteoporosis...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...ted with denosumab treatment was not statistically superior compared to Zometa (adjusted p=0.06) (secondary en...was also numerically greater but not statistically superior compared to Zometa (hazard ratio 0.90, 95 percent ...condary endpoints were to evaluate if denosumab is superior to Zometa with respect to the first on-study SRE, ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...four acute symptom control studies and a longer-term maintenance study that compared INVEGA(R) SUSTENNA(TM) to placebo. INVEGA(R) SUSTENNA(TM) was superior to placebo in improving positive and negative syndrome scale (PANSS) total scores in the acute treatment trials and significantly delayed time to rela...

Covance Receives Highest Level of Phase I Accreditation

...n," said Rob Aspbury, M.D., managing director, clinical research services, Covance. "As an industry leader in clinical pharmacology, Covance provides superior experience and expertise in study design and conduct to support today's increasingly complex first-in-human trials." MHRA accreditation was i...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

...val rate is 54% at a median follow up of 4.5 years (range 2.4 to 7.4) for the 30 surviving patients. Although not a direct comparison, the results are superior to those observed following vaccination with irradiated tumor cells in 48 melanoma patients in a previous trial (64 vs. 31 months, p=.016). Eight pati...

Neurointerventionists Expand Research to Quality of Life in Aneurysm Patients Following Minimally Invasive Coiling Treatment

...ysm Trial (ISAT) - which ultimately was halted due to overwhelming evidence that minimally invasive coiling (an endovascular therapy) was, on average, superior to traditional surgical clipping in the treatment of brain aneurysms - many studies have continued to prove the short- and long-term viability of this...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...that approximately 90 percent of the rat's 25,000-30,000 estimated genes are analogous to those in humans and mice, and their larger size makes them a superior model for drug-evaluation studies using serial sampling. Generating rats with knockout mutations has been a major challenge, but the new technique wi...

Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)

...toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available t...toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit ...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...ive Vice President, Research and Development, HGS. "We are delighted to report that the efficacy of treatment with BENLYSTA plus standard of care was superior in this study to that of placebo plus standard of care, while the safety profile was comparable overall to placebo. BENLYSTA met the primary endpoint...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

...s primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. Superiority was demo...ondary endpoints were to evaluate if denosumab was superior to Zometa with respect to the first on-study SRE, ...that have lower prices, established reimbursement, superior performance, are easier to administer, or that are...

BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis

...TEWL) during the 28-day period. Physician assessments, such as Eczema Area and Severity Index (EASI) were also evaluated. ProtoCure emulsion cream was superior to placebo in decreasing skin redness and improving skin barrier function. Statistically significant improvement was observed as early as day 10 after...

Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes

...one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate Web site, www.takeda.com . About Takeda Phar...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

... SEATTLE, June 22 /PRNewswire-FirstCall/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups Additional Clinical Studies Also Highlighted at Pan Paci...

EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health

...n the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties. EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann...

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients

...pleters from the pitavastatin treatment groups of the core study. The results of the core study demonstrated that pitavastatin was statistically superior to pravastatin across all three dose comparisons as measured by percent change from baseline in LDL-C ( P <.001), and that a higher percentage of p...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... patient populations treated with ACTEMRA, as measured by ACR response rates and DAS28 scores. ACTEMRA monotherapy was proven to be statistically superior to methotrexate in ACR20, ACR50 and ACR70 responses(4) (at six months), according to results of a post-hoc analysis of the AMBITION ( A ctemra versu...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

...tion of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limite...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

...Sciences Center at San Antonio. "Unfortunately, the majority of the BARI-2D patients did not receive drug-eluting stents, which have been shown to be superior to bare metal stents for diabetic patients. The standard of care has evolved since BARI-2D was initiated and many of the early patients in the trial ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

...ville G. Kolterman, M.D., senior vice president of research and development at Amylin. "In DURATION-1, exenatide once weekly has been shown to provide superior glycemic control, with weight loss, compared to BYETTA. If approved, this therapy could fill an important unmet need for treating patients with type 2...